Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240445 | 1.00 | HRH3 (0.58) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL22137596 | 0.83 | LTA4H (0.56) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL18824777 | 0.81 | HRH3 (0.56) | HRH3HRH1KCNH2 | |
| SCHEMBL18844624 | 0.81 | HRH3 (0.52) | HRH3MAOBHRH1KCNH2 | |
| SCHEMBL237631 | 0.80 | HRH3 (0.58) | HRH3HRH1KCNH2 | |
| SCHEMBL29455778 | 0.80 | BRD4 (0.44) | HRH3KCNH2 | |
| SCHEMBL4476224 | 0.78 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL1179056 | 0.78 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL85615 | 0.78 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 | |
| SCHEMBL4562819 | 0.78 | HRH3 (0.67) | HRH3MAOBHRH2HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2752406-A1 | Substituted pyridazine derivatives which have histamine H3 antagonist activity | CEPHALON, INC. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069312-B1 | PYRIDIZINONE DERIVATIVES | CEPHALON INC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2502918-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2492263-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | HRH3 4/4885MAOB 318/4885HRH2 9/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | HRH3 1/4885MAOB 36/4885HRH2 6/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885MAOB 37/4885HRH2 7/4885 |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885MAOB 478/4885HRH2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.